Aaron N Hata

List of Publications by Year
in descending order

66 papers	6,938 citations	117625 34 h-index	118850 62 g-index
68 all docs	68 docs citations	68 times ranked	10108 citing authors

#	Article	IF	Citations
1	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€“Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 2016, 22, 4585-4593.	7.0	977
2	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 2016, 22, 262-269.	30.7	768
3	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discovery, 2015, 5, 475-487.	9.4	501
4	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	9.4	429
5	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	9.4	342
6	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	1.6	246
7	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RASâ€“MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922.	9.4	243
8	Cycling cancer persister cells arise from lineages with distinct programs. Nature, 2021, 596, 576-582.	27.8	236
9	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	9.4	228
10	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	7.0	175
11	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	5.9	160
12	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	158
13	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery, 2019, 9, 1372-1387.	9.4	158
14	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discovery, 2018, 8, 600-615.	9.4	157
15	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nature Medicine, 2018, 24, 512-517.	30.7	155
16	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 2535-2545.	7.0	127
17	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research, 2019, 25, 6662-6670.	7.0	122
18	Programmed Cell Death Ligand (PD-L1) Expression inÂStage II and III Lung Adenocarcinomas and NodalÂMetastases. Journal of Thoracic Oncology, 2017, 12, 458-466.	1.1	120

#	Article	IF	Citations
19	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	7.1	110
20	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	16.8	106
21	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	16.8	104
22	The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature Communications, 2019, 10, 3604.	12.8	99
23	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	86
24	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Journal of Thoracic Oncology, 2016, 11, 1869-1878.	1.1	81
25	Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers, 2021, 13, 2666.	3.7	79
26	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clinical Cancer Research, 2018, 24, 197-208.	7.0	74
27	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	9.4	71
28	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research, 2014, 74, 3146-3156.	0.9	69
29	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusionâ€“Positive Lung Cancer. Clinical Cancer Research, 2021, 27, 2899-2909.	7.0	62
30	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56
31	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
32	Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. Science Advances, 2021, 7, .	10.3	49
33	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	17.5	48
34	Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature, 2019, 573, 139-143.	27.8	45
35	MET amplification (amp) as a resistance mechanism to osimertinib.. Journal of Clinical Oncology, 2017, 35, 9020-9020.	1.6	45
36	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Reports, 2019, 27, 3422-3432.e4.	6.4	42

#	Article	IF	Citations
37	Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clinical Cancer Research, 2018, 24, 5658-5672.	7.0	38
38	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
39	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 2021, 16, 850-859.	1.1	35
40	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Research, 2019, 79, 3776-3788.	0.9	32
41	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer, 2022, 3, 710-722.	13.2	28
42	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology, 2019, 14, e226-e228.	1.1	24
43	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	17
44	Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond. Cancer Discovery, 2020, 10, 20-22.	9.4	16
45	Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8012-8012.	1.6	16
46	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nature Communications, 2021, 12, 3697.	12.8	14
47	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine, 2022, 14, eabc7480.	12.4	14
48	Targeting the DNA replication stress phenotype of KRAS mutant cancer cells. Scientific Reports, 2021, 11, 3656.	3.3	10
49	Screening and Validation of Molecular Targeted Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e63-e74.	0.8	10
50	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€“Transformed EGFR Mutant Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 1, 1-7.	3.0	8
51	Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue. Clinical Cancer Research, 2020, 26, 2441-2443.	7.0	8
52	Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information. Nucleic Acids Research, 2022, 50, e68-e68.	14.5	8
53	Modeling Resistance and Recurrence Patterns of Combined Targetedâ€“Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Research, 2020, 80, 5121-5133.	0.9	7
54	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e21231-e21231.	1.6	6

#	Article	IF	Citations
55	MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state. Cancer Gene Therapy, 2022, 29, 1878-1894.	4.6	6
56	Distinct evolutionary paths to TKI resistance in NSCLC. Cell Cycle, 2018, 17, 298-299.	2.6	4
57	Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?. Cancer Research, 2020, 80, 25-26.	0.9	4
58	Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression.. Journal of Clinical Oncology, 2015, 33, 7554-7554.	1.6	4
59	Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8571-8571.	1.6	4
60	Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression.. Journal of Clinical Oncology, 2015, 33, 7555-7555.	1.6	3
61	Alginate-based 3D cancer cell culture for therapeutic response modeling. STAR Protocols, 2021, 2, 100391.	1.2	2
62	Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2019, 14, 1875-1877.	1.1	1
63	Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.. Journal of Clinical Oncology, 2022, 40, e21154-e21154.	1.6	1
64	Abstract 982:LKB1loss rewires stress signaling-induced apoptotic protein dynamics and sensitizesKRAS-mutant non-small cell lung cancers to combined MAPK + MCL-1 blockade. , 2021, , .		0
65	Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction. Cancer Research, 2022, 82, 1300-1300.	0.9	0
66	Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade. Cancer Research, 2022, 82, 2150-2150.	0.9	0